Knowledge and perception of hypercholesterolemia among Princess Nourah Bint Abdulrahman University students

Background: Hypercholesterolemia is one of the major risk factors for cardiovascular disease, which could escalate mortality rates in Saudi Arabia. Research has shown that the prevalence of high cholesterol in Saudi Arabia is predicted to rise in the next few years. The knowledge and perception are important as this is one of the modifiable risk factors for NCDs. The aim of study is to assess the knowledge and perception regarding hypercholesterolemia among university students and to determine if there is any relation between knowledge and perception of hypercholesterolemia among university students. Methods: A cross-sectional study using a self-administrated questionnaire measuring the knowledge and perception of hypercholesterolemia was conducted among 588 medical and non-medical students at Princess Nourah Bint Abdulrahman University. Results: The result indicates that 54.93% of the participants had poor knowledge about hypercholesterolemia and 79.76% of them had a positive perception about it. Conclusions: There is a gap in knowledge and perception regarding high cholesterol. Furthermore, it was found that there is a significant association between the knowledge and perception regarding hypercholesterolemia among Princess Nourah Bint Abdulrahman University students.

Asociación y riesgo de hipercolesterolemia en prediabéticos de un centro médico de Villa El Salvador, Lima, Perú / Association and risk of hypercholesterolemia among patients with prediabetes from a medical center in Villa El Salvador, Lima, Peru

RESUMEN Objetivo: Evaluar la asociación y el riesgo de hipercolesterolemia en pacientes adultos prediabéticos atendidos en un centro médico del distrito de Villa El Salvador en Lima, Perú. Materiales y métodos: Estudio analítico, prospectivo y transversal, con datos de historias clínicas de consultas médicas de 749 pacientes atendidos en un policlínico del distrito de Villa El Salvador, Lima, Perú. Se incluyó a pacientes adultos asintomáticos que asistieron a evaluaciones de rutina y preventivas. Se excluyó a pacientes con enfermedades endocrino-metabólicas o en tratamiento con fármacos hipoglucemiantes. Las variables de estudio fueron sexo, hipercolesterolemia y prediabetes. El análisis de asociación se realizó por medio de la prueba de chi cuadrado y el riesgo fue evaluado por medio de la oportunidad relativa; asimismo, se realizó el análisis multivariado por medio de regresión logística binaria y se consideró como punto de corte en decisión de significancia estadística el valor alfa igual a 0,05 y un nivel de confianza de 95 %. Resultados: Hubo asociación estadísticamente significativa entre prediabetes e hipercolesterolemia. Las mujeres prediabéticas tuvieron 1,66 veces más riesgo de desarrollar hipercolesterolemia que las mujeres con niveles de glucosa basal normales, mientras que los hombres con prediabetes tuvieron 2,37 veces más riesgo de tener colesterol alto que los hombres con niveles de glucemia basal normales. Conclusiones: La prediabetes se asocia con la hipercolesterolemia, lo cual aumenta su riesgo. Es justificable realizar la medición conjunta del colesterol total en ayunas junto con la medición de la glucosa basal en campañas preventivo-promocionales de salud y en consultas periódicas, así como durante el seguimiento de pacientes con factores de riesgo de diabetes, prediabetes e hipercolesterolemia, a fin de reducir las consecuencias hemodinámicas y cardiovasculares del colesterol elevado en la sangre y el agravamiento de la morbimortalidad conjunta de la hiperglucemia crónica.

ABSTRACT Objective: To evaluate the association and risk of hypercholesterolemia among adult patients with prediabetes treated at a medical center in the district of Villa El Salvador in Lima, Peru. Materials and methods: An analytical, prospective and cross-sectional study conducted with data from medical consultation records of 749 patients treated at a polyclinic in the district of Villa El Salvador in Lima, Peru. Asymptomatic adult patients who had routine and preventive checkups were included in the research. Patients with endocrine and metabolic disorders or being treated with hypoglycemic drugs were excluded. The study variables were sex, hypercholesterolemia and prediabetes. The association analysis was performed using the chi-square test and the risk was evaluated by means of the odds ratio. In addition, the multivariate analysis was conducted through a binary logistic regression, and an alpha value of 0.05 and a confidence level of 95 % were considered as the cut-off point to determine the statistical significance. Results: There was a statistically significant association between prediabetes and hypercholesterolemia. Females with prediabetes were 1.66 times more likely to develop hypercholesterolemia than females with normal baseline glucose levels, while males with prediabetes were 2.37 times more likely to have high cholesterol than males with normal baseline blood glucose levels. Conclusions: Prediabetes is associated with hypercholesterolemia, thus increasing its risk. It is justifiable to carry out the joint measurement of fasting total cholesterol and baseline glucose in disease prevention and health promotion campaigns, regular checkups and follow-up of patients with risk factors for diabetes, prediabetes and hypercholesterolemia. This helps reduce the hemodynamic and cardiovascular consequences of high cholesterol levels and the worsening of the joint morbidity and mortality of chronic hyperglycemia.

Prevalence of chronic diseases among residents in Xiamen City / 预防医学

Objective@#To investigate the prevalence of major chronic diseases among residents in Xiamen City, Fujian Province, so as to provide insights into enhancing the prevention and control of chronic diseases.@*Methods@#The residents aged 18 years and older and lived for 6 months and more were selected from 6 districts in Xiamen City from 2021 to 2022 using the stratified random sampling method. Demographic information, disease history, blood pressure, fasting blood glucose and blood cholesterol were collected through questionnaire surveys, physical examination and laboratory tests. The prevalence rates of hypertension, diabetes and hypercholesterolemia were calculated and standardized using the 2020 National Population Census data, and were analyzed by age and gender.@*Results@#Totally 22 289 residents were investigated, including 10 444 males (46.86%) and 11 845 females (53.14%). The prevalence rates of hypertension, diabetes and hypercholesterolemia were 15.35%, 4.30% and 10.45%, and the standardized prevalence rates were 16.25%, 4.81% and 10.21%, respectively. The standardized prevalence rates of hypertension, diabetes and hypercholesterolemia in males were 19.20%, 5.71% and 9.97%, respectively, and were higher than those in females, which were 13.62%, 4.03% and 10.29%, respectively (all P<0.05). The crude prevalence rates of hypertension and diabetes in males aged 18 to 59 years were higher than those in females, the crude prevalence rate of hypercholesterolemia in males aged 18 to 49 years was higher than that in females, and the crude prevalence rate of hypercholesterolemia aged 50 years and over in males was lower than that in females (all P<0.05).@*Conclusion@#From 2017 to 2022, the prevalence rates of hypertension, diabetes, and hypercholesterolemia in males were higher than those in females in Xiamen City, while the prevalence rate of hypercholesterolemia in females was higher than that in males after the age of 50 years.

Systematic review of pharmacoeconomic evaluation on PCSK9 inhibitors for the prevention of cardiovascular disease in patients with hypercholesterolemia / 中国药房

OBJECTIVE To systematically review the pharmacoeconomic evaluation literature about proprotein convertase subtilisin/kexin type 9 （PCSK9） inhibitors for the prevention of cardiovascular disease in patients with hypercholesterolemia， and to provide a reference for clinical treatment， health decision-making and future follow-up research. METHODS Retrieved from English and Chinese databases such as PubMed and CNKI， the pharmacoeconomic literature about PCSK9 inhibitors （evolocumab and alirocumab） for the prevention of cardiovascular disease in patients with hypercholesterolemia was collected from the establishment of the database to October 8， 2023. The quality of the included literature was assessed with Consolidated Health Economic Evaluation Reporting Standards 2022 （CHEERS 2022） scale. The descriptive analysis was performed for basic information， model structure， related parameters， sensitivity analysis and the results of included studies. RESULTS & CONCLUSIONS A total of 29 literature were included， with overall good quality. The evaluation mainly adopted the Markov model from the healthcare system， payer and societal perspective. The effectiveness and utility data mainly came from the previous studies； the direct cost was mainly considered with a discount rate of 1.5%-5.0% per year， while the willingness-to-pay threshold was often set at 1-3 times the gross domestic product per capita. Most health output indicators were measured in life years and quality-adjusted life years. The sensitivity analysis of most studies demonstrated the robustness and the main influential factor was the drug cost. Most Chinese studies showed that PCSK9 inhibitor was not cost-effective for the prevention of cardiovascular disease in patients with acute coronary syndrome， myocardial infarction and atherosclerotic cardiovascular disease. It was cost-effective to use PCSK9 inhibitors for the prevention of cardiovascular disease only in specific groups， such as patients with triple vessel disease， patients with newly diagnosed acute coronary syndrome and low-density lipoprotein cholesterol≥100 mg/dL. Future research should refer to the CHEERS 2022 scale to improve the design， and strive to select large-scale， high-quality data to enhance the quality of reports and the transparency of health decisions， so as to more accurately assess the cost-effectiveness of PCSK9 inhibitors.

Prevalence and factors associated with dyslipidemia in children aged 6 to 42 months in a Brazilian capital / Prevalência e fatores associados à dislipidemia em crianças de 6 a 42 meses de idade em uma capital brasileira / Prevalencia y factores asociados a dislipidemia en niños de 6 a 42 meses de edad en una capital brasileña

This study aimed to assess the prevalence and factors associated with lipid profile abnormalities of children aged 6 to 42 months in a Central-West Brazilian capital city. This cross-sectional study used data from the baseline of a cluster-randomized clinical trial conducted in parallel. It evaluated the lipid profile, usual nutrients intake (direct food-weighing method and 24-hour dietary recall), anthropometric parameters, and socioeconomic aspects of 169 children from early childhood education centers. Poisson regression with robust variance analysis was conducted. Of the total sample, 85% had dyslipidemia, 72% had high-density lipoproteins (HDL-c) levels below the desired range, 49% had increased triglycerides (TG), 17% exhibited elevated low-density lipoproteins (LDL-c), and 15% showed high total cholesterol (TC). An increase in the body mass index (BMI) for age z-score was associated with a higher prevalence of increased TG (PR = 1.22; 95%CI: 1.05-1.41; p = 0.009). Higher age in children was associated with an increased prevalence of high LDL-c (PR = 1.037; 95%CI: 1.01-1.07; p = 0.022) and TC (PR = 1.036; 95%CI: 1.00-1.07; p = 0.037), however it was a protective factor against low HDL-c (PR = 0.991; 95%CI: 0.98-1.00; p = 0.042). High energy intake was associated with low HDL-c (PR = 1.001; 95%CI: 1.00-1.00; p = 0.023). A higher prevalence of increased LDL-c (PR = 1.005; 95%CI: 1.00-1.01; p = 0.006) and decreased HDL-c (PR = 1.002; 95%CI: 1.00-1.00; p < 0.001) were associated with dietary cholesterol intake. Most of the children presented at least one alteration in serum lipids. Lipid profile abnormalities were associated with higher BMI, older age, and increased caloric and cholesterol intake.

O objetivo deste estudo foi avaliar a prevalência e os fatores associados às anormalidades do perfil lipídico de crianças de 6 a 42 meses de idade em uma capital do Centro-oeste do Brasil. Este estudo transversal utilizou dados da linha de base de um ensaio clínico randomizado por conglomerados realizado em paralelo. Avaliou-se o perfil lipídico, a ingestão habitual de nutrientes (método de pesagem direta de alimentos e recordatório alimentar de 24 horas), parâmetros antropométricos e aspectos socioeconômicos de 169 crianças de centros de educação infantil. Foi realizada uma regressão de Poisson com análise de variância robusta. Da amostra total, 85% apresentavam dislipidemia, 72% tinham níveis de lipoproteínas de alta densidade (HDL-c) abaixo da faixa desejada, 49% tinham triglicerídeos (TG) aumentados, 17% apresentavam lipoproteínas de baixa densidade (LDL-c) elevadas e 15% apresentavam colesterol total (CT) elevado. Um aumento no índice de massa corporal (IMC) para o escore z da idade foi associado a uma maior prevalência de aumento de TG (RP = 1,22; IC95%: 1,05-1,41; p = 0,009). A idade mais avançada das crianças foi associada a uma maior prevalência de LDL-c alto (RP = 1,037; IC95%: 1,01-1,07; p = 0,022) e CT (RP = 1,036; IC95%: 1,00-1,07; p = 0,037), mas foi um fator de proteção contra HDL-c baixo (RP = 0,991; IC95%: 0,98-1,00; p = 0,042). A alta ingestão de energia foi associada ao baixo HDL-c (RP = 1,001; IC95%: 1,00-1,00; p = 0,023). Uma maior prevalência de aumento de LDL-c (RP = 1,005; IC95%: 1,00-1,01; p = 0,006) e diminuição de HDL-c (RP = 1,002; IC95%: 1,00-1,00; p < 0,001) foi associada à ingestão de colesterol na dieta. A maioria das crianças apresentou pelo menos uma alteração nos lipídios séricos. As anormalidades do perfil lipídico foram associadas ao IMC mais alto, à idade mais avançada e ao aumento da ingestão calórica e de colesterol.

El objetivo de este estudio fue evaluar la prevalencia y los factores asociados con las anomalías del perfil lipídico en niños de 6 a 42 meses de edad en una ciudad del Centro-Oeste de Brasil. Este estudio transversal utilizó datos de referencia de un ensayo clínico aleatorizado por grupos realizado en paralelo. Se evaluó el perfil lipídico, la ingesta habitual de nutrientes (pesaje directo de alimentos y recordatorio de alimentación de 24 horas), los parámetros antropométricos y los aspectos socioeconómicos de 169 niños de centros de educación infantil. Se realizó una regresión de Poisson con un análisis robusto de la varianza. Se reveló que el 85% de los participantes tenían dislipidemia; el 72% presentaron niveles de lipoproteínas de alta densidad (HDL-c) por debajo del rango esperado; el 49% tenía aumento de triglicéridos (TG); el 17% de lipoproteínas de baja densidad (LDL-c) elevadas y el 15% tenía colesterol total (CT) elevado. Un aumento en el índice de masa corporal (IMC) para la puntuación z de la edad se asoció con una mayor tendencia a aumento de TG (RP = 1,22; IC95%: 1,05-1,41; p = 0,009). La edad más avanzada de los niños se asoció con una mayor prevalencia de LDL-c alta (RP = 1,037; IC95%: 1,01-1,07; p = 0,022) y CT (RP = 1,036; IC95%: 1,00-1,07; p = 0,037), pero fue un factor de protección contra HDL-c baja (RP = 0,991; IC95%: 0,98-1,00; p = 0,042). La ingesta alta de energía se asoció con HDL-c baja (RP = 1,001; IC95%: 1,00-1,00; p = 0,023). Se encontraron que la mayor tendencia a aumento de LDL-c (RP = 1,005; IC95%: 1,00-1,01; p = 0,006) y disminución de HDL-c (RP = 1,002; IC95%: 1,00-1,00; p < 0,001) estuvieron asociadas con la ingesta de colesterol en la dieta. La mayoría de los niños tuvieron al menos un cambio en los lípidos séricos. Las anomalías del perfil lipídico se asociaron con un mayor IMC, mayor edad y mayor consumo de calorías y colesterol.

Análise de metabólitos secundários presentes nas plantas Cynara scolymus L e Artemisia absinthium L durante o tratamento de dislipidemias / Analysis of secondary metabolites present in the plants Cynara scolymus L and Artemisia absinthium L during the treatment of dyslipidemia

O uso de plantas medicinais como forma de tratamento para várias doenças é uma tradição que se estende entre gerações, há milhares de anos. Os povos antigos costumavam usar partes específicas de alguns vegetais para a realização de chás e curativos para feridas. Ainda nos dias atuais, muitas pessoas preferem as formas naturais como tratamento para suas comorbidades, principalmente como adjuvantes no combate às dislipidemias. O presente trabalho teve o objetivo de analisar as plantas Cynara scolymus L e Artemisia absinthium L para confirmar a presença ou ausência de proteases específicas contra a hipercolesterolemia. A pesquisa foi realizada através de uma triagem das plantas no software RCSB (https://www.rcsb.org/). No final, pode-se confirmar que a planta Cynara scolymus L atende às perspectivas de tratamento da hipercolesterolemia, enquanto a Artemisia absinthium L não apresentou valores suficientes que sejam eficazes no tratamento.

The use of medicinal plants as a form of treatment for various diseases is a tradition that has spanned generations for thousands of years. Ancient people used to use specific parts of some vegetables to make teas and dressings for wounds. Even today, many people prefer natural forms as a treatment for their comorbidities, especially as adjuvants in the fight against dyslipidemia. The present work aimed to analyze the plants Cynara scolymus L and Artemisia absinthium L to confirm the presence or absence of specific proteases against hypercholesterolemia. The research was carried out by screening the plants using the RCSB software (https://www.rcsb.org/). In the end, it can be confirmed that the Cynara scolymus L plant meets the prospects for treating hypercholesterolemia, while Artemisia absinthium L did not present sufficient values that are effective in the treatment.

Sitosterolemia caused by mutations in the ABCG8 gene. First case report in Colombia / Sitosterolemia causada por mutaciones en el gen ABCG8. Primer reporte de caso en Colombia

Abstract Introduction: Sitosterolemia is an autosomal recessive disease caused by mutations in the ABCG5 or ABCG8 genes. It is characterized by reduced excretion of plant sterols and cholesterol, leading to the development of hypercholesterolemia, xanthomas, and premature atherosclerosis. The present article reports the first case of this disease in Colombia. Case presentation: A 5-year-old child, son of non-consanguineous parents, who was under active treatment with ezetimibe and cholestyramine was taken (April 2021) to the human genetics service of a healthcare institution in Bogotá, Colombia, for assessment due to multiple xanthomas and elevated LDL cholesterol levels. Familial hypercholesterolemia had been ruled out. A next-generation gene sequencing (NGS) analysis detected a mutation in the ABCG8 gene, so he was diagnosed with sitosterolemia. Pharmacological treatment (ezetimibe and cholestyramine) was continued and dietary modifications were started. In the last follow-up visit of the patient to the human genetics service (March 2022), an improvement in the lipid profile was observed. In addition, 9 months later (December 2022), a decrease in the size of the xanthomas was reported in an evaluation by the pediatric endocrinology service. Conclusion: Sitosterolemia is a rare disease that should be considered in pediatric patients with multiple xanthomas and in whom familial hypercholesterolemia has been ruled out. Performing NGS of the genes involved is important to make a timely diagnosis and initiate appropriate treatment, which will improve the prognosis and quality of life of these patients.

Resumen Introducción. La sitosterolemia es una enfermedad de herencia autosómica recesiva causada por mutaciones en los genes ABCG5 o ABCG8 que se caracteriza por la disminución de la excreción de esteroles vegetales y de colesterol, lo que conduce al desarrollo de hipercolesterolemia, xantomas y aterosclerosis prematura. En el presente artículo se reporta el primer caso de esta enfermedad registrado en Colombia. Presentación del caso. Varón de 5 años, hijo de padres no consanguíneos, en tratamiento activo con ezetimiba y colestiramina, quien fue llevado (abril 2021) al servicio de genética humana de una institución de salud en Bogotá, Colombia, para valoración debido a que tenía múltiples xantomas, niveles elevados de colesterol LDL y a que se había descartado diagnóstico de hipercolesterolemia familiar. Mediante análisis de secuenciación génica de nueva generación (NGS) se detectó mutación del gen ABCG8, por lo que se diagnosticó sitosterolemia y se decidió continuar el tratamiento farmacológico (ezetimiba y colestiramina) e iniciar modificaciones dietarías. En el último control del paciente con el servicio de genética humana (marzo 2022) se observó mejoría en el perfil lipídico. Además, 9 meses después (diciembre 2022), en una valoración por el servicio de endocrinología pediátrica se evidenció una disminución en el tamaño de los xantomas. Conclusión. La sitosterolemia es una enfermedad inusual que debe tenerse en cuenta en pacientes pediátricos con xantomas múltiples y en los que se haya descartado hipercolesterolemia familiar, por lo que realizar una NGS de los genes implicados es importante para realizar un diagnóstico oportuno e iniciar el tratamiento adecuado, lo que mejorará el pronóstico y calidad de vida de estos pacientes.

Ruta colombiana del colesterol. Mesa redonda nacional sobre el colesterol en Colombia. Llamado a la acción / Colombian Cholesterol Roadmap. National roundtable on cholesterol in Colombia. Call to action

Resumen La enfermedad cardiovascular aterosclerótica (infarto de miocardio, accidente cerebrovascular y enfermedad arterial periférica) continúan siendo las causas más importantes de muerte prematura, discapacidad y gastos en atención médica en todo el mundo. Por lo tanto, evitar la acumulación vascular de lipoproteínas aterogénicas de colesterol es fundamental para prevenir los eventos cardiovasculares mayores. La actualización de la ruta colombiana del colesterol, Colombian Cholesterol Roadmap, es el resultado de la reunión realizada en el Congreso Nacional de Cardiología 2023, con el apoyo de la Federación Mundial del Corazón y una mesa de expertos clínicos, temáticos y representantes de diferentes instituciones relacionadas con el manejo de las dislipidemias en Colombia. Este documento tiene como objetivo ser un marco conceptual para describir los hallazgos y logros obtenidos a partir de las mesas de trabajo relacionadas con la identificación de barreras que limitan el tratamiento adecuado de la hipercolesterolemia en Colombia y las acciones que fueron propuestas ajustadas al contexto local que buscan desarrollar políticas nacionales y enfoques en nuestros sistemas de salud. Así mismo, confirma el compromiso del trabajo articulado intersectorial para lograr las metas en salud cardiovascular propuestas para el año 2030.

Abstract Atherosclerotic cardiovascular diseases (including myocardial infarction, stroke, and peripheral arterial disease) continue to be a leading cause of premature death, disability, and healthcare expenditures worldwide. Therefore, preventing the vascular accumulation of atherogenic cholesterol-containing lipoproteins is crucial in averting major cardiovascular events. The Colombian Cholesterol Roadmap update is the outcome of a meeting held during the 2023 National Cardiology Congress, with the support of the World Heart Federation and a panel of clinical and thematic experts, along with representatives from various institutions involved in the management of dyslipidaemias in Colombia. The present update of this Cholesterol Roadmap provides a conceptual framework to describe the findings and achievements derived from working groups focused on identifying barriers that hinder the appropriate treatment of hypercholesterolemia in Colombia. It also outlines proposed actions adjusted to the local context, aiming to develop national policies and approaches within our healthcare systems. Furthermore, it reaffirms the commitment to intersectoral collaboration to achieve the cardiovascular health goals set for the year 2030.

Carga económica de la hipercolesterolemia en población con alto riesgo cardiovascular en México / Economic burden of hypercholesterolemia in high risk of cardiovascular disease population in Mexico

Resumen Objetivo: Se estimó la carga económica directa e indirecta de la hipercolesterolemia en población con alto riesgo de presentar un evento cardiovascular. Para ello se definieron específicamente cinco grupos de pacientes: 1) aquellos con hipercolesterolemia familiar; 2, 3 y 4) personas con hipercolesterolemia más el antecedente de diabetes, infarto o evento vascular cerebral; 5) pacientes con hipercolesterolemia más diabetes y antecedente de infarto agudo de miocardio (definidos como pacientes de muy alto riesgo cardiovascular). Los cálculos se hicieron desde la perspectiva de las instituciones de salud pública en México. Método: Para la estimación de los costos directos se incluyó la atención ambulatoria, el tratamiento farmacológico, la atención hospitalaria y las intervenciones quirúrgicas relacionadas con las enfermedades cardiovasculares. Para la carga económica indirecta, se consideraron las muertes reportadas específicamente por causa de hipercolesterolemia, en un momento anterior al final de la edad productiva (muerte prematura). Resultados: La carga económica directa de las cinco categorías de pacientes en riesgo consideradas es de MXN $39,601,464,154 (USD $1,987,526,432), mientras que la carga económica indirecta asciende a MXN $121,646,689 (USD $6,105,229). Conclusiones: El impacto económico de la hipercolesterolemia en población con alto riesgo cardiovascular correspondía a $39,723,110,843 en 2020 (equivalente a USD $1,993,631,661), equivalente al 0.16% del PIB nacional.

Abstract Objective: To estimate the direct and indirect economic burden of hypercholesterolemia in patients with high risk of a cardiovascular event, specifically there were defined 5 groups of patients: 1) familial hypercholesterolemia; 2, 3 and 4) patients with hypercholesterolemia and background of diabetes, myocardial infarction or stroke; 5) diabetes, myocardial infarction and hypercholesterolemia (very high-risk patients) from the Mexican public healthcare institutions. Methods: For the estimation of the direct costs the items included correspond to: outpatient care, pharmacological treatment, inpatient hospital care, and surgical procedures. For indirect economic burden, death certificates, before the end of the productive age due to hypercholesterolemia were calculated (premature mortality). Results: The direct economic burden for the 5 groups of patients at risk is MXN $39,601,464,154 (USD $1,987,526,432), while the indirect economic burden amounts to MXN $121,646,689 (USD $6,105,229). Conclusions: The economic impact of hypercholesterolemia in patients with high cardiovascular risk is $39,723,110,843 (equivalent to USD $1,993,631,661) and corresponds to the 0.16% of GDP.

Perspectiva de los médicos de atención primaria sobre el manejo de la dislipemia en pacientes sin enfermedad cardiovascular aterosclerótica: estudio transversal / Perspective of primary care physicians on the management of dyslipidaemia in patients without atherosclerotic cardiovascular disease: a cross-sectional study

ANTECEDENTES: un alto porcentaje de pacientes con dislipemia no alcanza los objetivos terapéuticos de colesterol unido a lipoproteínas de baja densidad (C-LDL) en el nivel primario de atención. Objetivo: Describir el manejo terapéutico de la dislipemia en pacientes sin enfermedad cardiovascular aterosclerótica (ECA) establecida, desde la perspectiva del médico de atención primaria en España. MATERIAL Y MÉTODOS: Estudio transversal mediante encuesta electrónica dirigida a médicos de atención primaria para explorar su manejo terapéutico farmacológico de la dislipemia en pacientes sin ECA, que se centraba en su conocimiento y adherencia a las guías de la Sociedad Europea de Cardiología/Sociedad Europea de Aterosclerosis (ESC/AES) de 2019 y su perspectiva con respecto a las barreras para alcanzar los objetivos de C-LDL. RESULTADOS: Un total de 279 médicos de atención primaria completaron la encuesta. La mayoría (80,65%) afirmaron que ya habían adoptado las guías de la ESC/EAS de 2019 en su práctica. Sin embargo, alrededor del 30% seguía los objetivos terapéuticos de las guías anteriores (2016) y muchos trataban a sus pacientes con estatinas en monoterapia y dosis menores a la máxima tolerada. Adicionalmente un 50,18% era poco adherente a las guías de la ESC/EAS de 2019, especialmente al algoritmo de tratamiento. Las barreras más importantes para alcanzar los objetivos de C-LDL eran la subestimación del riesgo cardiovascular y la reticencia a aumentar la dosis o a utilizar terapia combinada. Conclusiones: Aunque los médicos de atención primaria afirman que seguían las guías ESC/EAS de 2019, los resultados indican que no las habían integrado completamente en su práctica clínica.

BACKGROUND: Evidence suggests many dyslipidemic patients do not reach target low-density lipoprotein and cholesterol (LDL-C) levels in primary health care. OBJETIVE: We aimed to describe the pharmacologic therapeutic management of dyslipidemia in patients without established atherosclerotic cardiovascular diseases (ASCVD) from the primary care physician's perspective in Spain. Material and Methods: We conducted a cross-sectional study through an online survey directed to primary care physicians to explore their therapeutic management of dyslipidemia in patients without ASCVD, focusing on their knowledge and adherence to the 2019 European Society of Cardiology/ European Atherosclerosis Society (ESC/EAS) guidelines and their perspective concerning the barriers to achieving LDL-C therapeutic targets. RESULTS: In total, 279 primary care physicians completed the survey. Most interviewees (80.65%) stated they had already adopted the 2019 ESC/EAS guidelines in their clinical practice. Nevertheless, around 30% adhered to therapeutic targets by previous ESC/EAS guidelines (2016), and most treated their patients mainly with statins in monotherapy, prescribing doses below the maximum tolerated. Additionally, 50.18% were classified as low adherence to the 2019 ESC/EAS guidelines, especially to the treatment algorithm. According to the physicians, the underestimation of patients' cardiovascular risk and the reluctance to increase doses or use combined therapy were the most critical barriers to achieving LDL-C targets. Conclusions: Although primary care physicians in our survey reported adherence to the 2019 ESC/EAS guidelines recommendations, our observations indicate they need to integrate them better into their clinical practice.

Tendencia del programa de intervención en DemoMinga, como estrategia para mejorar las dislipidemias y glucemia en la población Norma Luisa, Minga Guazú

Antecedentes: Las enfermedades no transmisibles siguen siendo un problema creciente en el mundo, sobre todo en los países de mediano y bajo ingresos. Los programas de intervención comunitaria se enfocan en su disminución mediante cambios en estilos de vida más saludables. Objetivos: Analizar la tendencia del programa de intervención en actividad física y nutrición, como estrategia para mejorar las dislipidemias y glucemia en los participantes del proyecto DemoMinga. Materiales y métodos: Estudio con enfoque cuantitativo. Diseño de investigación acción participativa, de carácter longitudinal, prospectivo. La población estuvo constituida por los participantes del Proyecto DemoMinga. Se determinó en cada participante: colesterol total, triglicéridos y glucemia en ayunas. Las muestras fueron procesadas en el Centro de Investigaciones Médicas de la FACISA-UNE. Se determinaron indicadores de tendencia central (mediana) de cada una de las variables. Resultados: Hubo mayor participación del sexo femenino, con predominio de personas con menos de 45 años. Las mediciones químicas arrojaron una tendencia de disminución a partir del quinto año de intervención, con talleres de cocina saludable incluyendo uso de aceite alto oleico, y actividad física. Sin embargo, la prueba no arrojó diferencias significativas de las mediciones entre la línea de base y el corte a los 6 años. Conclusión: El estudio resalta la importancia de los programas de intervención mediante terapias integrales para la promoción y prevención de las enfermedades cardiometabólicas a largo plazo.

Background: Non-communicable diseases remain a growing problem worldwide, especially in middle and low-income countries. Community intervention programs are focused on reducing their prevalence through promoting healthier lifestyle changes. Objectives: To analyze the trend of the physical activity and nutrition intervention program as a strategy to improve dyslipidemia and glycemia among participants of the DemoMinga project. Materials and methods: This study employed a quantitative approach with a participatory action research design, characterized as longitudinal and prospective. The population consisted of participants from the DemoMinga Project. For each participant, total cholesterol, triglycerides, and fasting glycemia were measured. Samples were processed at the Medical Research Center of FACISA-UNE. Indicators of central tendency (median) were determined for each of the variables. Results: There was a higher participation of females, with a predominance of individuals under the age of 45. Chemical measurements showed a decreasing trend starting from the fifth year of intervention, involving healthy cooking workshops that included the use of high oleic oil and physical activity. However, the test did not yield significant differences in measurements between the baseline and the 6-year cutoff. Conclusion: The study highlights the significance of intervention programs using comprehensive therapies for the long-term promotion and prevention of cardiometabolic diseases.

Tendencia del programa de intervención en DemoMinga, como estrategia para mejorar las dislipidemias y glucemia en la población Norma Luisa, Minga Guazú / Trend of the DemoMinga intervention program as a strategy to improve dyslipidemia and glycemia in the Norma Luisa population, Minga Guazú

Antecedentes: Las enfermedades no transmisibles siguen siendo un problema creciente en el mundo, sobre todo en los países de mediano y bajo ingresos. Los programas de intervención comunitaria se enfocan en su disminución mediante cambios en estilos de vida más saludables. Objetivos: Analizar la tendencia del programa de intervención en actividad física y nutrición, como estrategia para mejorar las dislipidemias y glucemia en los participantes del proyecto DemoMinga. Materiales y métodos: Estudio con enfoque cuantitativo. Diseño de investigación acción participativa, de carácter longitudinal, prospectivo. La población estuvo constituida por los participantes del Proyecto DemoMinga. Se determinó en cada participante: colesterol total, triglicéridos y glucemia en ayunas. Las muestras fueron procesadas en el Centro de Investigaciones Médicas de la FACISA-UNE. Se determinaron indicadores de tendencia central (mediana) de cada una de las variables. Resultados: Hubo mayor participación del sexo femenino, con predominio de personas con menos de 45 años. Las mediciones químicas arrojaron una tendencia de disminución a partir del quinto año de intervención, con talleres de cocina saludable incluyendo uso de aceite alto oleico, y actividad física. Sin embargo, la prueba no arrojó diferencias significativas de las mediciones entre la línea de base y el corte a los 6 años. Conclusión: El estudio resalta la importancia de los programas de intervención mediante terapias integrales para la promoción y prevención de las enfermedades cardiometabólicas a largo plazo.

Background: Non-communicable diseases remain a growing problem worldwide, especially in middle and low-income countries. Community intervention programs are focused on reducing their prevalence through promoting healthier lifestyle changes. Objectives: To analyze the trend of the physical activity and nutrition intervention program as a strategy to improve dyslipidemia and glycemia among participants of the DemoMinga project. Materials and methods: This study employed a quantitative approach with a participatory action research design, characterized as longitudinal and prospective. The population consisted of participants from the DemoMinga Project. For each participant, total cholesterol, triglycerides, and fasting glycemia were measured. Samples were processed at the Medical Research Center of FACISA-UNE. Indicators of central tendency (median) were determined for each of the variables. Results: There was a higher participation of females, with a predominance of individuals under the age of 45. Chemical measurements showed a decreasing trend starting from the fifth year of intervention, involving healthy cooking workshops that included the use of high oleic oil and physical activity. However, the test did not yield significant differences in measurements between the baseline and the 6-year cutoff. Conclusion: The study highlights the significance of intervention programs using comprehensive therapies for the long-term promotion and prevention of cardiometabolic diseases.

Advances in diagnosis and treatment of familial hypercholesterolemia / 南方医科大学学报

Familial hypercholesterolemia (FH) is an autosomal dominant inherited disease caused by abnormal lipoprotein metabolism. Patients with FH have a significantly increased risk of coronary artery disease (CAD) due to long-term exposure to high levels of low-density lipoprotein (LDL). The diagnosis of FH relies heavily on gene detection, and examination of LDL receptor (LDLR) function is of great significance in its treatment. This review summarizes the current advances in the screening, diagnosis, and treatment of FH and functional analysis of LDLR gene mutations.

Development of the novel ACLY inhibitor 326E as a promising treatment for hypercholesterolemia

Hepatic cholesterol accumulation is an important contributor to hypercholesterolemia, which results in atherosclerosis and cardiovascular disease (CVD). ATP-citrate lyase (ACLY) is a key lipogenic enzyme that converts cytosolic citrate derived from tricarboxylic acid cycle (TCA cycle) to acetyl-CoA in the cytoplasm. Therefore, ACLY represents a link between mitochondria oxidative phosphorylation and cytosolic de novo lipogenesis. In this study, we developed the small molecule 326E with an enedioic acid structural moiety as a novel ACLY inhibitor, and its CoA-conjugated form 326E-CoA inhibited ACLY activity with an IC50 = 5.31 ± 1.2 μmol/L in vitro. 326E treatment reduced de novo lipogenesis, and increased cholesterol efflux in vitro and in vivo. 326E was rapidly absorbed after oral administration, exhibited a higher blood exposure than that of the approved ACLY inhibitor bempedoic acid (BA) used for hypercholesterolemia. Chronic 326E treatment in hamsters and rhesus monkeys resulted in remarkable improvement of hyperlipidemia. Once daily oral administration of 326E for 24 weeks prevented the occurrence of atherosclerosis in ApoE-/- mice to a greater extent than that of BA treatment. Taken together, our data suggest that inhibition of ACLY by 326E represents a promising strategy for the treatment of hypercholesterolemia.

Compound Danshen Dripping Pill inhibits hypercholesterolemia/atherosclerosis-induced heart failure in ApoE and LDLR dual deficient mice via multiple mechanisms

Heart failure is the leading cause of death worldwide. Compound Danshen Dripping Pill (CDDP) or CDDP combined with simvastatin has been widely used to treat patients with myocardial infarction and other cardiovascular diseases in China. However, the effect of CDDP on hypercholesterolemia/atherosclerosis-induced heart failure is unknown. We constructed a new model of heart failure induced by hypercholesterolemia/atherosclerosis in apolipoprotein E (ApoE) and LDL receptor (LDLR) dual deficient (ApoE-/-LDLR-/-) mice and investigated the effect of CDDP or CDDP plus a low dose of simvastatin on the heart failure. CDDP or CDDP plus a low dose of simvastatin inhibited heart injury by multiple actions including anti-myocardial dysfunction and anti-fibrosis. Mechanistically, both Wnt and lysine-specific demethylase 4A (KDM4A) pathways were significantly activated in mice with heart injury. Conversely, CDDP or CDDP plus a low dose of simvastatin inhibited Wnt pathway by markedly up-regulating expression of Wnt inhibitors. While the anti-inflammation and anti-oxidative stress by CDDP were achieved by inhibiting KDM4A expression and activity. In addition, CDDP attenuated simvastatin-induced myolysis in skeletal muscle. Taken together, our study suggests that CDDP or CDDP plus a low dose of simvastatin can be an effective therapy to reduce hypercholesterolemia/atherosclerosis-induced heart failure.

Metabolomics study on improvement effects of Cirsium japonicum extract on hypercholesterolemia model mice / 中国药房

OBJECTIVE To explore the mechanism of Cirsium japonicum extract in improving hypercholesterolemia based on metabolomics technology. METHODS The extract of C. japonicum was prepared by macroporous resin adsorption， and its main components were identified by liquid chromatography-tandem mass spectrometry. The experimental mice were randomly divided into control group （n＝6） and modeling group （n＝16）. The hypercholesterolemia model was induced by diet in modeling group； after modeling， the rats of modeling group were divided into model group （n＝8） and C. japonicum extract group （n＝8）. C. japonicum extract group was given C. japonicum extract 400 mg/（kg·d） by gavage （calculated by extract）， and other 2 groups were given constant volume of 0.3% sodium carboxymethyl cellulose solution， for 6 weeks. After medication， the intervention effect of C. japonicum extract was evaluated by the levels of serum total cholesterol （TC）， triglyceride （TG） and the histopathological changes of liver. The mechanism of C. japonicum extract in improving hypercholesterolemia model mice was investigated by metabolomics. RESULTS It was identified that C. japonicum extract contained 12 components， such as 030302005） chlorogenic acid， linarin and pectolinarin. After 6 weeks of intervention， compared with control group， serum level of TC was increased significantly while the level of TG was decreased significantly in model group （P＜0.05）， while a large number of lipid droplets， disorderly arrangement of liver cells and the damaged structure of liver cord were observed in liver tissue. Compared with model group， the serum level of TC was decreased significantly in C. japonicum extract group（P＜0.05）； the lipid droplets in liver tissue were significantly reduced， with liver cells arranged radially and tightly centered around the central vein， and liver cords arranged neatly. The metabolomics study showed that after the intervention of C. japonicum extract， the levels of metabolites were significantly adjusted back， such as ethanolamine， fumaric acid and cholesterol； finally， three metabolism pathways， such as alanine-aspartate-glutamic acid metabolism， arginine biosynthesis， citric acid cycle， were obtained. CONCLUSIONS The main components of C. japonicum extract are phenolic acids and flavonoids， such as chlorogenic acid， linarin， pectolinarin. C. japonicum extract can improve hypercholesterolemia by regulating the contents and distribution of differential metabolites， adjusting alanine-aspartate-glutamic acid metabolism， arginine biosynthesis and citric acid cycle， participating in oxidation-reduction reaction， improving liver lipid accumulation， and playing anti-inflammatory role.

A Case Report of Homozygous Familial Hypercholesterolemia Liver Transplantation / 罕见病研究

Homozygous familial hypercholesterolemia (HoFH) is a rare and serious autosomal genetic metabolic disease. Patients without intervention often die younger than 30 years old from early atherosclerotic cardiovascular disease (ASCVD)incurred by extremely high levels of low-density lipoprotein cholesterol (LDL-C). We present a case of HoFH, a child with compound heterozygous mutation in this study. The effect of conventional lipid-lowering therapy through diet control and lipid-lowering drugs was unsatisfactory. The blood-lipid purification proves effective but has poor compliance and difficult to maintain for a longer time. The patient received orthotopic liver transplantation and had been followed for 2 years, with the patient shows normal LDL-C, well growth and development. We hope the case will provide the clinician with better understanding of the diagnosis and treatment of the rare disease of HoFH.

Familial Hypercholesterolemia / 罕见病研究

Familial hypercholesterolemia (FH) is a group of autosomal co-dominant genetic diseases mainly characterized by abnormal low-density lipoprotein related metabolism. It is one of the most common inherited diseases in children and one of the most serious lipid metabolism diseases which results in various life-threatening cardiovascular diseases and the complications. In recent years, the treatment protocols for FH have diversified thanks to the deeper understanding of the disease in China and abroad and the development of new lipid-lowering drugs. However, the current awareness and diagnosis rate of FH are very low. The treatment of the disease is much inadequate. This paper summarizes the clinical characteristics, diagnosis, screening strategy, and treatment of FH hoping to enhance the understanding and awareness of the disease in the society.

An Early Onset of Myocardial Infarction Patient with Syphilis and Familial Hypercholesterolemia / 罕见病研究

Syphilis may affect the cardiovascular system, in which coronary arteries are less commonly involved. Familial hypercholesterolemia (FH) is an autosomal dominant inherited disease with elevated low-density lipoprotein-cholesterol (LDL-C) levels due to impaired LDL-C clearance. We report a young male patient with syphilis and FH. The clinical manifestations were acute myocardial infarction and high LDL-C levels. Coronary angiography and intracoronary imaging showed multiple aneurysmal ectasia and stenosis. A drug-eluting stent was implemented when recurrent restenosis occurred after two percutaneous coronary drug-eluting balloon angioplasties.

Clinical research advances of liver transplantation for patients with familial hypercholesterolemia / 中华器官移植杂志

Familial hypercholesterolemia(FH)is an autosomal dominant disease.Homozygous FH patients tend to have a high incidence of severe arteriosclerotic cardiovascular disease during adolescence and die at ages of 20-30.Liver transplantation(LT)may correct the dysfunction of LDL receptor on hepatocytes, restore normal lipoprotein metabolism, arrest disease progression and improving patient outcomes.However, due to a great rarity of LT for FH, domestic transplantation centers lack the relevant clinical experiences.This review summarized some important issues of FH patients undergoing LT, such as indications, timing, donor sources, efficacies, complications and reusing diseased liver.The goal was to provide practical references for managing FH.